• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SGLT2 inhibitors in people with and without T2DM.

作者信息

Khunti Kamlesh

机构信息

Diabetes Research Centre, University of Leicester, Leicester, UK.

出版信息

Nat Rev Endocrinol. 2021 Feb;17(2):75-76. doi: 10.1038/s41574-020-00453-2.

DOI:10.1038/s41574-020-00453-2
PMID:33293703
Abstract
摘要

相似文献

1
SGLT2 inhibitors in people with and without T2DM.有和没有2型糖尿病的人群中的钠-葡萄糖协同转运蛋白2抑制剂
Nat Rev Endocrinol. 2021 Feb;17(2):75-76. doi: 10.1038/s41574-020-00453-2.
2
Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria.评估钠-葡萄糖协同转运蛋白2抑制剂对慢性肾脏病合并蛋白尿患者心肾疗效的专用肾脏结局试验的荟萃分析。
Am J Cardiol. 2021 Jan 1;138:116-118. doi: 10.1016/j.amjcard.2020.10.007. Epub 2020 Oct 9.
3
Dapagliflozin Cut Risk of Worsening Heart Failure.达格列净降低心力衰竭恶化风险。
JAMA. 2020 Jan 28;323(4):301. doi: 10.1001/jama.2019.22087.
4
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.恩格列净与 2 型糖尿病、已确诊心血管疾病和慢性肾脏病患者的临床结局。
Circulation. 2018 Jan 9;137(2):119-129. doi: 10.1161/CIRCULATIONAHA.117.028268. Epub 2017 Sep 13.
5
Introduction.引言。
Am J Cardiol. 2017 Jul 1;120(1S):S1-S3. doi: 10.1016/j.amjcard.2017.05.008. Epub 2017 May 30.
6
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
7
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.恩格列净对伴或不伴糖尿病的心力衰竭患者心血管和肾脏结局的影响：来自 EMPEROR-Reduced 试验的结果。
Circulation. 2021 Jan 26;143(4):337-349. doi: 10.1161/CIRCULATIONAHA.120.051824. Epub 2020 Nov 11.
8
Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.SGLT2 抑制剂的肾脏和心血管保护机制评估：基于模型的临床数据分析。
Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1295-F1306. doi: 10.1152/ajprenal.00202.2018. Epub 2018 Jul 18.
9
Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.恩格列净降低2型糖尿病合并心血管疾病患者的心血管死亡率
J Am Coll Cardiol. 2018 Jan 23;71(3):364-367. doi: 10.1016/j.jacc.2017.11.022.
10
Dapagliflozin (Farxiga) - a new indication for heart failure.达格列净（安达唐）——心力衰竭的新适应症。
Med Lett Drugs Ther. 2020 Jun 29;62(1601):102-103.

引用本文的文献

1
Bexagliflozin on Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.贝西格列净对2型糖尿病肾脏结局的影响：一项随机对照试验的系统评价和荟萃分析
Cureus. 2025 Apr 17;17(4):e82458. doi: 10.7759/cureus.82458. eCollection 2025 Apr.
2
The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications.糖尿病性射血分数保留的心力衰竭中新型抗糖尿病药物的概况：相关机制及临床意义
Cardiovasc Diabetol. 2025 Apr 28;24(1):186. doi: 10.1186/s12933-025-02750-4.
3
An overview of obesity-related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes.
肥胖相关并发症概述：将体重及其他肥胖指标与不良健康结局联系起来的流行病学证据。
Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):3-19. doi: 10.1111/dom.16263. Epub 2025 Mar 11.
4
Uninephrectomy and sodium-glucose cotransporter 2 inhibitor administration delay the onset of hyperglycemia.单侧肾切除和钠-葡萄糖共转运蛋白 2 抑制剂给药可延缓高血糖的发生。
Physiol Rep. 2024 Nov;12(21):e70121. doi: 10.14814/phy2.70121.
5
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies.钠-葡萄糖共转运蛋白 2 抑制剂在有肾结石或痛风既往史患者中预防肾结石复发的效果比较：真实世界试验模拟研究。
BMJ. 2024 Oct 30;387:e080035. doi: 10.1136/bmj-2024-080035.
6
Insulin Resistance in Long COVID-19 Syndrome.长新冠综合征中的胰岛素抵抗
J Pers Med. 2024 Aug 28;14(9):911. doi: 10.3390/jpm14090911.
7
New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family.钠-葡萄糖协同转运蛋白2抑制剂对心肾的益处及miR-30家族协同作用的新见解。
Genes Dis. 2023 Nov 23;11(6):101174. doi: 10.1016/j.gendis.2023.101174. eCollection 2024 Nov.
8
Serum urate change among gout patients treated with sodium-glucose cotransporter type 2 inhibitors vs. sulfonylurea: A comparative effectiveness analysis.钠-葡萄糖共转运蛋白 2 抑制剂与磺脲类药物治疗痛风患者的血清尿酸变化：一项比较效果分析。
Semin Arthritis Rheum. 2024 Jun;66:152441. doi: 10.1016/j.semarthrit.2024.152441. Epub 2024 Apr 5.
9
The clinical benefits of sodium-glucose cotransporter type 2 inhibitors in people with gout.钠-葡萄糖共转运蛋白 2 抑制剂在痛风患者中的临床获益。
Nat Rev Rheumatol. 2024 Apr;20(4):216-231. doi: 10.1038/s41584-024-01092-x. Epub 2024 Mar 12.
10
Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation.恩格列净通过抑制Bhlhe40依赖性NLRP3炎性小体激活改善糖尿病小鼠的血管钙化。
Acta Pharmacol Sin. 2024 Apr;45(4):751-764. doi: 10.1038/s41401-023-01217-0. Epub 2024 Jan 3.